Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of biologic treatment response by ex vivo immunological testing in rheumatoid arthritis
NL-OMON26414Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of abatacept, adalimumab, etanercept, rituximab and tocilizumab in rheumatoid arthritis (RA) (5 cohorts), sponsored by Sint Maartenskliniek. Primary endpoint: EULAR good response at 3 months. Started Jun 2014; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON26414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26414.